<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281149</url>
  </required_header>
  <id_info>
    <org_study_id>TOMO-1307</org_study_id>
    <nct_id>NCT02281149</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy:</brief_title>
  <acronym>TOMO</acronym>
  <official_title>Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy: Evaluation of the Toxicity and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adjuvant radiotherapy after lumpectomy allows a local long-term control of the order 85 to
      95% with a survival rate equivalent to that of the totally mastectomy. The diminution of the
      local recurrence rate after irradiation post- lumpectomy is also associated to a best global
      survival than only the surgery. The adjuvant radiotherapy after partially or totally
      mastectomy for the progressive tumors is a therapeutic standard (Early Breast Cancer
      Trialists' Collaborative Group 2011). The aim of our trial of routine care is to record our
      practices under this breast adjuvant radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients responding criteria for selection and not objecting to participate in this trial
      will address the quality of life questionnaires at baseline and during their standard
      follow-up (1, 6, 12 and 24 months after the end of radiotherapy). The data of toxicity and
      disease-free survival will be collected from data on medical record of the patient.

      The therapeutic support and monitoring are standard.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>acute and tardive toxicity according to NCI-CTCAE v4.0</measure>
    <time_frame>up to 36 months</time_frame>
    <description>according to NCI-CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 36 months</time_frame>
    <description>according to QLQC-30 and BR-23 module</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>up to 36 months</time_frame>
    <description>according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>esthetic results</measure>
    <time_frame>up to 36 months</time_frame>
    <description>by physician and patient according to a scale (good, excellent, moderate and poor)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        prospective study of routine care done on women with breast cancer treated by adjuvant
        radiotherapy with intensity modulated
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1-Patient with breast cancer proved by histology and treated surgically 2. Relevant of
        adjuvant radiotherapy after partial or total mastectomy with or without lymph node
        irradiation 3- Age ≥ 18 years 4- Information and no opposition to the patient

        Exclusion Criteria:

          1. - Metastatic disease

          2. - Patient having another severe disease or uncontrolled which could jeopardize the
             trial participation

          3. - pregnant or breastfeeding woman 4-inability to do follow-up medical care of clinical
             trial for geographical, social or psychological reasons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquier David, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Decoupigny Emilie, ARC</last_name>
    <phone>33 3 20 29 59 18</phone>
    <email>e-decoupigny@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thénot-Maricourt Aurélie, QA Manager</last_name>
    <phone>33 3 20 29 59 18</phone>
    <email>a-thenot@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Decoupigny Emilie, ARC</last_name>
      <phone>33 3 20 29 59 18</phone>
      <email>e-decoupigny@o-lambret.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thénot-Maricourt Aurélie, QA Manager</last_name>
      <phone>33 3 20 29 59 18</phone>
      <email>a-thenot@o-lambret.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pasquier David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>intensity modulation</keyword>
  <keyword>toxicity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

